Does Dr. SOFIA ACCORDINO have financial conflicts of interest?

Dr. SOFIA ACCORDINO (MD) has received a total of $100 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $100 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. SOFIA ACCORDINO?

According to CMS Open Payments data, Dr. SOFIA ACCORDINO received funding from SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US ($82), MYLAN PHARMACEUTICALS ($15), and GENENTECH USA ($3).

Does Dr. SOFIA ACCORDINO receive research grants or speaking fees?

Dr. SOFIA ACCORDINO has received $100 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. SOFIA ACCORDINO

MDReal-Time Hydrated

Specialty: Physician Assistant

Practice Location: YOUNGSTOWN, OH 44504

NPI Number: 1093350688

LIFETIME INDUSTRY VALUE

$100

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ACCORDINO is a verified Physician Assistant practitioner based in YOUNGSTOWN, OH.

Between 2021 and 2025, Dr. ACCORDINO had an overall industry promotional and research financial footprint of $100 as recorded in the federal CMS Open Payments database.

$100 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ACCORDINO's primary funding source is SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US, which accounts for $82 (representing 81.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US

Rank 1

$82

81.9%

MYLAN PHARMACEUTICALS

Rank 2

$15

14.7%

GENENTECH USA

Rank 3

3.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.